MedTrace Logo

Progressive Relaxation and Psychoeducation in Patients With Hematological Malignancies

NCT07251348 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2026-05-15

No results posted yet for this study

Summary

This study will be conducted to determine the effect of progressive relaxation and psychoeducation on perceived stress and hope in patients with hematological malignancies

Conditions

  • Hematological Cancer

Interventions

BEHAVIORAL

Muscle Relaxation

Progressive relaxation is a relaxation technique based on tensing and relaxing muscles in sequence. The goal is to achieve physical and mental relaxation by feeling the difference between tension and relaxation. It is frequently used for stress, anxiety, sleep problems, and psychosomatic disorders. When practiced regularly, it increases a person's ability to relax and contributes to their overall well-being. * Teaching progressive relaxation exercises to individuals diagnosed with cancer and supporting psychological well-being by reducing stress levels and increasing hope levels through these exercises (emotional gain) * Reducing muscle tension and providing physical relaxation (psychomotor gain) * To reduce stress and anxiety (emotional gain) * To increase body awareness (emotional gain) * To teach mental and physical relaxation (psychomotor gain) * To provide emotional relief (emotional gain) * To develop self-relaxation skills (psychomotor gain)

BEHAVIORAL

psychoeducation or Atomoxetine or stimulants according to ADHD severity

Psychoeducation is a structured educational process that provides individuals with information about mental illnesses, ways to cope with stress, and healthy living skills. The goal is to help the person understand their illness and symptoms, learn coping methods, and increase their compliance with treatment. It has both an informative and a supportive aspect. INTERVENTION B (PSYCHOEDUCATION) GROUP APPLICATION: * A total of 6 sessions will be held with patients in intervention group B, twice a week for 3 weeks. * Each session will last an average of 45 minutes. * The 'Perceived Stress Level' scale and the 'Herth Hope Index' scale will be administered after the first session. * The 'Perceived Stress Level' scale and the 'Herth Hope Index' scale will be administered after the final session.

Sponsors & Collaborators

  • Necmettin Erbakan University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-01
Primary Completion
2026-11-30
Completion
2026-11-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07251348 on ClinicalTrials.gov